SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Sep. 30, 2022

Revenue by payor class as a percentage of total net service revenue is as follows:


	For the Three-Month Periods Ended September 30,				For the Nine-Month Periods Ended September 30,
	2022		2021		2022		2021
Home Health:
Medicare	40	%	41	%	40	%	41	%
Non-Medicare - Episodic-based	7	%	8	%	8	%	8	%
Non-Medicare - Non-episodic based	13	%	12	%	13	%	12	%
Hospice:
Medicare	34	%	34	%	33	%	34	%
Non-Medicare	2	%	2	%	2	%	2	%
Personal Care	3	%	3	%	3	%	3	%
High Acuity Care (1)	1	%	—	%	1	%	—	%
	100	%	100	%	100	%	100	%

(1) Acquired Contessa Health on August 1, 2021.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of September 30, 2022		As of December 31, 2021
Cash and cash equivalents	$	18.0	$	42.7
Restricted cash	13.5		3.1
Cash, cash equivalents and restricted cash	$	31.5	$	45.8

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of September 30, 2022		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	457.4	$	—	$	473.4	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Three- Month Periods Ended September 30,		For the Nine- Month Periods Ended September 30,
	2022	2021	2022	2021
Weighted average number of shares outstanding - basic	32,482	32,607	32,519	32,658
Effect of dilutive securities:
Stock options	38	113	50	135
Non-vested stock and stock units	96	179	111	228
Weighted average number of shares outstanding - diluted	32,616	32,899	32,680	33,021
Anti-dilutive securities	202	141	276	82